This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Youn H. Kim, MD; Kay Bishop, MD; Anna Varghese; Richard T. Hoppe, MD

Arch Dermatol. 1995;131(9):1003-1008.

Abstract
Background and Design
There are no large studies evaluating patients with erythrodermic mycosis fungoides and Sézary syndrome to determine the important prognostic factors that may influence survival. This is important since new treatment modalities have been proposed as superior to existing primary therapies. We performed a retrospective cohort study of 106 patients with erythrodermic mycosis fungoides and Sézary syndrome, followed up in the Stanford (Calif) Mycosis Fungoides Clinic, to define the important prognostic factors in this group.

Results
Patients younger than 65 years have a more favorable survival profile than those 65 years or older (P<.005). Longer duration of symptoms before diagnosis (10 years) tends to be associated with more favorable prognosis (P=.055). Lymph node stage is significantly correlated with survival; patients with overall stage III disease have more favorable prognosis than those with stage IV disease (P<.001). Patients with circulating Sézary cells in their blood have a significantly worse prognosis than those without (P<.005). Patient sex or race had no significant effect on overall survival outcome. Three distinct prognostic groups were identified, ''favorable,'' ''intermediate,'' and ''unfavorable,'' according to the number of unfavorable prognostic factors (P<.005). The median survival in each group is 10.2,3.7, and 1.5 years, respectively.

Conclusions
In patients with erythrodermic mycosis fungoides and Sézary syndrome, the important prognostic factors are patient age at presentation, the overall stage, and peripheral blood involvement. Survival varies widely, depending on these variables. These prognostic factors should be evaluated when analyzing survival and/or treatment efficacy data of these patients.

(Arch Dermatol. 1995;131:1003-1008)

Author Affiliations
From the Departments of Dermatology (Drs Kim and Bishop) and Radiation Oncology (Ms Varghese and Dr Hoppe), Stanford (Calif) University School of Medicine. There were no outside sources of support for this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How I treat mycosis fungoides and Sezary syndrome
Prince et al.
Blood 2009;114:4337-4353.
ABSTRACT | FULL TEXT  

CXCL13 Is Highly Produced by Sezary Cells and Enhances Their Migratory Ability via a Synergistic Mechanism Involving CCL19 and CCL21 Chemokines
Picchio et al.
Cancer Res. 2008;68:7137-7146.
ABSTRACT | FULL TEXT  

Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy
Nebozhyn et al.
Blood 2006;107:3189-3196.
ABSTRACT | FULL TEXT  

Durable Clinical, Cytogenetic, and Molecular Remissions After Allogeneic Hematopoietic Cell Transplantation for Refractory Sezary Syndrome and Mycosis Fungoides
Molina et al.
JCO 2005;23:6163-6171.
ABSTRACT | FULL TEXT  

Impaired CD40L signaling is a cause of defective IL-12 and TNF-{alpha} production in Sezary syndrome: circumvention by hexameric soluble CD40L
French et al.
Blood 2005;105:219-225.
ABSTRACT | FULL TEXT  

Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT | FULL TEXT  

A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories
Herling et al.
Blood 2004;104:328-335.
ABSTRACT | FULL TEXT  

Long-term Outcome of 525 Patients With Mycosis Fungoides and Sezary Syndrome: Clinical Prognostic Factors and Risk for Disease Progression
Kim et al.
Arch Dermatol 2003;139:857-866.
ABSTRACT | FULL TEXT  

Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma
Kari et al.
JEM 2003;197:1477-1488.
ABSTRACT | FULL TEXT  

Circulating CD4+CD7- Lymphocyte Burden and Rapidity of Response: Predictors of Outcome in the Treatment of Sezary Syndrome and Erythrodermic Mycosis Fungoides With Extracorporeal Photopheresis
Stevens et al.
Arch Dermatol 2002;138:1347-1350.
ABSTRACT | FULL TEXT  

Treatment of Cutaneous T-Cell Lymphoma With Combined Immunomodulatory Therapy: A 14-Year Experience at a Single Institution
Suchin et al.
Arch Dermatol 2002;138:1054-1060.
ABSTRACT | FULL TEXT  

Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sezary Syndrome
Bouwhuis et al.
Mayo Clin Proc. 2002;77:197-200.
ABSTRACT  

Update in Dermatology
Kazin et al.
ANN INTERN MED 2001;135:124-132.
FULL TEXT  

Phase 2 and 3 Clinical Trial of Oral Bexarotene (Targretin Capsules) for the Treatment of Refractory or Persistent Early-Stage Cutaneous T-Cell Lymphoma
Duvic et al.
Arch Dermatol 2001;137:581-593.
ABSTRACT | FULL TEXT  

Clinical Characteristics and Outcome of Patients With Extracutaneous Mycosis Fungoides
de Coninck et al.
JCO 2001;19:779-784.
ABSTRACT | FULL TEXT  

Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma
Scarisbrick et al.
Blood 2001;97:624-630.
ABSTRACT | FULL TEXT  

Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma
Delfau-Larue et al.
Blood 2000;96:2987-2992.
ABSTRACT | FULL TEXT  

Effectiveness of Photopheresis in Sezary Syndrome
Stevens et al.
Arch Dermatol 1999;135:995-997.
FULL TEXT  

Expression of Cytotoxic Proteins by Neoplastic T Cells in Mycosis Fungoides Increases with Progression from Plaque Stage to Tumor Stage Disease
Vermeer et al.
Am. J. Pathol. 1999;154:1203-1210.
ABSTRACT | FULL TEXT  

Clinical Characteristics and Long-term Outcome of Patients With Generalized Patch and/or Plaque (T2) Mycosis Fungoides
Kim et al.
Arch Dermatol 1999;135:26-32.
ABSTRACT | FULL TEXT  

Extracorporeal Photopheresis in Sezary Syndrome: No Significant Effect in the Survival of 44 Patients With a Peripheral Blood T-Cell Clone
Fraser-Andrews et al.
Arch Dermatol 1998;134:1001-1005.
ABSTRACT | FULL TEXT  

Clinical Stage IA (Limited Patch and Plaque) Mycosis Fungoides: A Long-term Outcome Analysis
Kim et al.
Arch Dermatol 1996;132:1309-1313.
ABSTRACT  

Wide Variation in Prognosis of Sezary Syndrome
Journal Watch Dermatology 1995;1995:6-6.
FULL TEXT  

Is Cutaneous T-Cell Lymphoma Curable?
Koh et al.
Arch Dermatol 1995;131:1081-1082.
ABSTRACT